We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

45 hedge funds and large institutions have $8.4M invested in Protalix BioTherapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

880% more call options, than puts

Call options by funds: $98K | Put options by funds: $10K

138% more capital invested

Capital invested by funds: $3.53M → $8.4M (+$4.87M)

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

1.3% more ownership

Funds ownership: 4.67% → 5.97% (+1.3%)

0% more funds holding

Funds holding: 45 → 45 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

Holders
45
Holders Change
–
Holders Change %
0%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
8
Closed
8
Calls
$98K
Puts
$10K
Net Calls
+$88K
Net Calls Change
+$63K

Top Buyers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
+$961K
2
Renaissance Technologies
Renaissance Technologies
New York
+$229K
3
Morgan Stanley
Morgan Stanley
New York
+$180K
4
Marshall Wace
Marshall Wace
United Kingdom
+$144K
5
Jane Street
Jane Street
New York
+$95.7K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$183K
2
OGF
Orin Green Financial
California
-$102K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$72.2K
4
SA
Sanctuary Advisors
Indiana
-$62.7K
5
XT
XTX Topco
Cayman Islands
-$35.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
PI
26
PFG Investments
New York
$39K +$29.3K +20,730 New
YIH
27
Y-Intercept (HK)
Hong Kong
$35.4K +$26.6K +18,818 New
UBS Group
28
UBS Group
Switzerland
$34.2K +$25.3K +17,886 +6,125%
Lido Advisors
29
Lido Advisors
California
$29.2K – – –
KAS
30
Kestra Advisory Services
Texas
$26.3K -$2.83K -2,000 -13%
AS
31
Altshuler Shaham
Israel
$22.8K – – –
CFM
32
Catalyst Funds Management
Australia
$19.2K – – –
HIM
33
Harbour Investment Management
Washington
$19K – – –
TWC
34
TD Waterhouse Canada
Ontario, Canada
$11.1K – – –
TC
35
Truvestments Capital
Florida
$4.62K – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$3K – – –
Lazard Asset Management
37
Lazard Asset Management
New York
$2K +$1.77K +1,255 New
PD
38
Point72 (DIFC)
United Arab Emirates
$1.69K -$15.1K -10,699 -92%
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$1.35K +$1.01K +716 New
Group One Trading
40
Group One Trading
Illinois
$1.23K +$928 +656 New
Citigroup
41
Citigroup
New York
$1.19K +$894 +632 New
AWM
42
Activest Wealth Management
Florida
$564 – – –
FDCDDQ
43
Federation des caisses Desjardins du Quebec
Quebec, Canada
$470 – – –
YDMI
44
Y.D. More Investments
Israel
$414 – – –
Osaic Holdings
45
Osaic Holdings
Arizona
$376 – – –
AAP
46
Arax Advisory Partners
Colorado
$74 – – –
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
– -$72.2K -70,817 Closed
SA
48
Sanctuary Advisors
Indiana
– -$62.7K -37,100 Closed
XT
49
XTX Topco
Cayman Islands
– -$35.8K -35,058 Closed
FI
50
Finivi Inc
Massachusetts
– -$14.8K -14,544 Closed
1
2
3

PLX Hedge Fund Activity: Q4 2024 in Review

45 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2024, worth a combined $8.4M — up 138% from $3.53M a quarter earlier.

Fund positioning in PLX was balanced in Q4 2024: 8 funds opened new positions, 8 closed out, 12 added to existing stakes and 8 trimmed.

The largest buyer was Northern Trust, adding an estimated $961K. The largest seller was GSA Capital Partners, cutting an estimated $183K.

  • 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $8.4M of Protalix BioTherapeutics stock for Q4 2024, up 138% quarter-over-quarter.
  • 8 funds opened new Protalix BioTherapeutics positions in Q4 2024 and 8 closed out, a net change of 0 holders.
  • The largest Protalix BioTherapeutics buyer in Q4 2024 was Northern Trust, an estimated $961K added.
  • The largest Protalix BioTherapeutics seller in Q4 2024 was GSA Capital Partners, an estimated $183K sold.

Based on aggregated 13F filings for Q4 2024.